[A18-59] Dabrafenib (melanoma) - Benefit assessment according to §35a Social Code Book V
Last updated 22.03.2019
Project no.:
A18-59
Commission:
Commission awarded on 24.09.2018 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adjuvant treatment of adult patients with stage III melanoma with a BRAF V600 mutation, following complete resection
Advantage in overall survival and recurrence, disadvantages in side effects; indication of considerable added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A17-17 | Dabrafenib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A15-39 | Dabrafenib (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A13-35 | Dabrafenib - Benefit assessment according to § 35a Social Code Book V (dossier assessment) | Commission completed |
| G19-05 | Dabrafenib (melanoma) - Addendum to Commission A18-59 | Commission completed |
| G24-07 | Dabrafenib (high-grade malignant glioma in paediatric patients aged 1 year and older, in combination with trametinib) – Assessment according to §35a SGB V (1), Sentence 11 | Commission completed |
Federal Joint Committee (G-BA)
2019-03-22 A G-BA decision was published.